Pravastatin vs Atorvastatin: PROVE IT TIMI 22 Study
Updated: Sep 8
Cannon CP et al conducted a clinical study (PROVE IT TIMI 22) to assess the benefits of intensive statin therapy vs. moderate statin therapy in preventing death from any cause or major cardiovascular events in patients with acute coronary syndrome (ACS). The objective is to establish the noninferiority of pravastatin vs atorvastatin.
Study Summary
About the Author
Mrs. Purnima Reddy Katkuri is a scientific writer with 4+ years of experience in content development and medical communications. Her passion for precision and attention to detail made her a reliable writer known for delivering high-quality scientific content to pharma clients. She has proven skills in editing and proofreading scientific documents while conforming to medical style guide. Her drafts are clear, correct, concise, and creative.
Abbreviations
UA: Unstable Angina; ACS: Acute Coronary Syndrome; MI: Myocardial Infarction;
Reference
Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504.
Disclaimer
The content published on this platform has been developed by independent medical writers from diverse healthcare backgrounds, including members of the MedWriters Alumni Network. While every effort has been made to ensure accuracy, the authors, Rxnews team, partners, agents, and sponsors accept no responsibility for errors, omissions, or inaccuracies in this article, whether due to negligence or otherwise, nor for any consequences arising from its use. Inclusion or exclusion of any product does not imply endorsement or rejection by the publisher. For complaints or feedback, please write to contact@rxnews.in
Comments